Bristol Myers Squibb Selects Houston for $2.3 Billion Multi-Modal Manufacturing Campus
核心洞察
Bristol Myers Squibb (搜索) announced a $2.3 billion investment to build a state-of-the-art multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs.
The 600,000-square-foot modular facility at Generation Park will manufacture small molecules (搜索), biologics (搜索), and antibody-drug conjugates (搜索) across multiple disease areas.
The investment is part of BMS' $40 billion five-year commitment to U.S. research, development, technology, and domestic manufacturing.
Bristol Myers Squibb (搜索) (BMS) has selected Houston, Texas, as the site for a new $2.3 billion state-of-the-art multi-modal manufacturing campus, the company announced on August 10, 2026. The facility, to be built at Generation Park, represents a significant expansion of the company's domestic manufacturing footprint and is designed to accelerate the delivery of next-generation medicines to patients.
The 600,000-square-foot campus will create nearly 500 skilled jobs and is designed to grow in scale, capability, and workforce for decades to come. The selection of Houston marks a significant milestone in BMS' $40 billion commitment to invest in the United States over five years across research and development, technology, and domestic manufacturing.
"This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb (搜索). "As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."
Modular and Multi-Modal Design for Pipeline Flexibility
From day one, the Houston campus will be modular and multi-modal. Its modular design allows BMS to add and reconfigure manufacturing capacity as needed, reflecting the company's current and future pipeline. The multi-modal capabilities enable BMS to manufacture multiple types of medicines — such as small molecules (搜索), biologics (搜索), and antibody-drug conjugates (搜索) — across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch.
"This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities," said Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb (搜索). "It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands."
The campus architecture allows new manufacturing capabilities to be brought online rapidly as pipeline and commercial needs evolve. It is also built for adaptability, with configuration flexibility that anticipates future advances in digital integration and automation.
Economic Impact and Job Creation
The new BMS campus is projected to employ nearly 500 people initially, with roles spanning operations technicians, production specialists, maintenance and engineering professionals, quality control and assurance experts, and site leadership and administration. BMS also expects to create approximately 2,000 construction and other indirect jobs between 2027 and 2030 as the facility is built and brought online.
Texas Governor Greg Abbott praised the investment, stating, "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare. This $2.3 billion investment by Bristol Myers Squibb (搜索) in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities."
A Texas Enterprise Fund grant of $4.89 million has been extended to BMS for the project, and the expansion also qualifies under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.
Strengthening U.S. Biopharmaceutical Leadership
BMS selected Texas and Generation Park following an extensive, competitive evaluation of multiple markets in the Central and Eastern U.S. Key factors included the emerging strength of the local workforce in life sciences, available incentives, proximity to utilities and transportation infrastructure, and an overall business climate conducive to long-term growth.
At 4,300 acres, Generation Park is a curated hub for life sciences and advanced manufacturing. The U.S. biopharmaceutical industry drives nearly $117 billion of research annually and employs more than 300,000 manufacturing employees. BMS invested approximately $10 billion in research and development in 2025.
"We are making pharmaceuticals in America again thanks to President Trump's America First Trade Agenda," said U.S. Secretary of Commerce Howard Lutnick. "Bristol Myers Squibb (搜索)'s $2.3 billion investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines."
BMS currently works with a contract manufacturer in Texas for both commercial and clinical trial manufacturing and, in 2025, had 250 clinical trial sites throughout the state to advance clinical research across its portfolio.